were inhaled into the lungs in a blinded, randomized fashion by 12 healthy volunteers. Blood samples were taken before and 4 h after the administration of the drug, and total lymphocyte count and different subpopulations were determined. In the second study, 15 healthy volunteers were randomized to BUD (1600 mg), FP (1600 mg), or placebo inhaled into the lungs. Blood samples were taken before and 4, 8, 24, 48 , and 148 h (=7 days) after inhalation of the medication.
Results: Neither the nasal applications nor the inhalation of FP (1500 mg/1600 mg) showed signi®cant differences in total lymphocyte count or different subpopulations between baseline and 4 h after the administration. In both studies, a signi®cant reduction was found in the total lymphocyte count, B cells, T cells, and the CD4+ and the CD8+ fractions 4 h after application of BUD 1600 mg.
Conclusions: Nasal application of BUD or FP in doses up to 800 mg do not induce lymphopenia. BUD 1600 mg inhalation in the lung reduces lymphocytes and their subfractions. Further studies have to be done to determine whether the results obtained in this study in healthy volunteers will also be found in patients with diseased mucosa and whether there is any correlation with adverse effects such as growth inhibition or osteoporosis.
For many years, local corticosteroid treatment has been the treatment of choice in moderate to severe rhinitis and asthma (1±3). Although modern inhaled corticosteroids have all aimed at a high topical anti-in¯ammatory effect combined with low systemic bioavailability, it has not been possible to remove all metabolic effects and isolate desired anti-in¯ammatory properties totally. Inhaled steroids are presently prescribed to large numbers of (young) patients, in large doses and for long periods.
Hence, there has been an increasing interest in the potential systemic effects of inhaled corticosteroids. These putative effects may include bone loss; skin thinning; and metabolic, hematologic, and immunologic effects (4) . Most studies concerning safety use tests of adrenal function to measure systemic effects, cortisol production over 1 day being the most sensitive method (5, 6) . A review of the available studies in asthma and healthy volunteers by Pedersen & O'Byrne indicated that, of the corticosteroids used in this study, the ef®cacy and the systemic potency ratio of¯uticasone propionate (FP) are usually found to be higher than budesonide (BUD) (7) . There seems to be a marked individual variation in the susceptibility to systemic effects of local corticosteroids (4) . However, at present, there is no simple or effective way to predict individual steroid susceptibility.
It has long been known that corticosteroids can produce lymphopenia and eosinopenia parentally (8) ; similar effects, although less pronounced, have been shown to occur with the use of inhaled steroids in the lung (9, 10) . No data are available on these effects after nasal application. The effects of inhaled steroids on the cellular components of blood do not seem to be clinically signi®cant. However, they can be used to study the amount of systemic uptake of different steroids or at different locations. Potentially, the effects on blood cells can also be used to study differences in individual susceptibility.
In the present study, the effect of locally inhaled corticosteroids in the nose and lung on blood lymphocytes was measured in healthy subjects. 
Material and methods
BANS: budesonide aqueous nasal spray; FPANS:¯uticasone propionate aqueous nasal spray. Budesonide 1600 mg and¯uticasone propionate 1500 mg were inhaled into lungs. Total number of lymphocytes showed signi®cant reduction after application of budesonide 1600 mg (P=0.02). None of other applications resulted in signi®cant reduction of lymphocytes. Percentages of lymphocyte subpopulations did not change after drug application. Volunteers: study 2
For further elucidation of the ®ndings in study 1, a second study was performed to check for reproducibility of the assay and diurnal variation. A double-blind, double-dummy, crossover study was performed to compare BUD 1600 mg, FP 1600 mg, and placebo at four time points during the day after inhalation and (for the active medication) also after 48 h and 7 days.
Fifteen healthy volunteers, median age 23 years (range 19± 31), seven women, eight men, participated in this study.
None of the volunteers were taking any medication. None of the volunteers had a history of rhinitis or asthma symptoms.
All volunteers had normal lung function. Budesonide 1600 mg and¯uticasone propionate 1600 mg were inhaled into lungs. Total number of lymphocytes showed signi®cant reduction 4 h after application of budesonide 1600 mg (P=0.002) compared to placebo. Signi®cant reduction was also found 4 h after inhalation of budesonide 1600 mg compared to placebo in CD4+ (P=0.001) and CD8+ fractions (P=0.009) of T cells and total number of B cells (P=0.002). No signi®cant differences were found at other time points. Nor were signi®cant differences found after inhalation of¯uticasone propionate 1600 mg. *P value active treatment vs placebo ,0.01. 
Statistical analysis
Data were analyzed by the SPSS for Windows 6.1 package.
Data were described with box plots (median, 25th, and 75th percentiles, the smallest (largest) value not more than 1.5 box lengths from the 25th (75th) percentile. Measurements between baseline and 4 h in study 1 were analyzed by the nonparametric paired Mann-Whitney U test. In study 2, carry-over effects were measured by comparing the sums of the two randomization groups. Differences between treatments and placebo at different time points were analyzed by the nonparametric paired Mann-Whitney U test. To compensate for multiple testing, a P value smaller than 0.01 was called signi®cant.
Results

Study 1
Box plots for the total number of lymphocytes, and number of B cells and CD4+ and CD8+ lymphocytes at baseline and after 4 h for the different treatments are shown in Fig. 1 . For the total number of lymphocytes, a signi®cant reduction was found only after inhalation of BUD 1600 mg (P=0.02). A signi®cant reduction was also found in the total number of T cells (P=0.02), the CD4+ (P=0.02) and the CD8+ fractions (P=0.01), and the total number of B cells (P=0.03) after inhalation of BUD 1600 mg (Fig. 1b) . No signi®cant differences were found between the parameters with any other application. Nor was a signi®cant reduction found in the percentages of various lymphocyte subpopulations (Table 1A) compared to the total number of lymphocytes.
However, large individual differences were found. After inhalation of BUD 1600 mg, three subjects had a reduction of total lymphocyte count of more than 40%, while one patient did not have any reduction. After inhalation of FP 1500 mg, the largest reduction was 22%. Three subjects did not have a reduction. No signi®cant correlation was found between the reduction after BUD 1600 mg and the reduction after FP 1500 mg (r=0.23).
Study 2
For further elucidation of the ®ndings in study 1, a second study was performed to check for reproducibility of the assay and (Table 1B) . No signi®cant differences were found at other time points. Nor were signi®cant differences found after inhalation of FP 1600 mg (Table 1B) . Although marked differences were found between subjects who responded to corticosteroids and those who hardly responded, no signi®cant correlation was found between the reduction after BUD 1600 mg and that after FP 1600 mg. It is not clear whether the results obtained in this study in healthy volunteers will also be found in the diseased mucosa normally seen in rhinitis and asthma. Moreover, it is not clear how long the reduction of lymphocytes after daily inhalation of BUD 1600 mg will persist, nor whether it has any clinical signi®cance or is correlated with (other) adverse effects such as growth inhibition or osteoporosis. Further studies are in progress to answer these questions. For now, this ""marginalization test'' might be a promising tool to study the systemic availability of locally administered corticosteroids.
Discussion
